期刊
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
卷 119, 期 2, 页码 569-576出版社
ELSEVIER TAIWAN
DOI: 10.1016/j.jfma.2019.04.012
关键词
Choroidal neovascularization; PCV; Photodynamic therapy; Vascular endothelial growth factors; Wet age-related macular degeneration
资金
- Taiwan Retina Society
Polypoidal choroidal vasculopathy (PCV) is a prevalent retinal disease predominantly occurs in Asians that shares some similarities seen in neovascular age-related macular degeneration. Recent large multicenter clinical trials on intravitreal anti-vascular endothelial growth factor (VEGF) agents and photodynamic therapy (PDT) have shed lights on the management of PCV. The Taiwan National Health Insurance had granted limited anti-VEGF agents and PDT for patients with PCV after the approval of required data submission, especially fundus angiography, optical coherence tomography, and visual acuity. In order to best utilize these limited resources for the patients, an expert meeting was held to provide updated Taiwan consensus recommendations for the management of PCV, including initial therapy selection, assessment of treatment response, re-treatment/rescue treatment, and determination of treatment extension/follow-up schedule. An algorithm for treatment allocation under both initial and re-treatment setting was proposed. Further mechanistic and clinical studies are required to investigate the prognostic factors and optimal treatment protocols that will improve healthcare quality and reduce burden of disease and treatment for patients with PCV. Copyright (C) 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据